NEW YORK (GenomeWeb News) — Pharmacy benefits manager Medco Health Solutions and LabCorp will use Roche’s AmpliChip to study why some women react to the breast cancer drug tamoxifen and other don’t, LabCorp and Medco said today.
Terms of the deal call for Medco to use Roche’s AmpliChip CYP450 test to study how tamoxifen is able to treat some forms of breast cancer while preventing the disease in certain high-risk populations. Approximately 10 percent of women using tamoxifen do not “fully benefit” from the drug because of variations in genes encoding drug metabolizing enzymes.
The firms penned their alliance in response to a US Food and Drug Administration Advisory Group recommendation last year that tamoxifen carry a warning label stating that it “may not work as well in postmenopausal women” who have a certain variant of the CYP450 gene family.
Medco Chief Medical Officer Robert Epstein said the license with LabCorp is part of a strategy to partner with personalized medicine companies.
Myla Lai-Goldman, chief scientific officer and medical director of LabCorp, added that the collaboration “will benefit patients and lower healthcare costs by improving outcomes, enhancing safety and reducing ineffective drug regimens.”
Financial terms of the agreement were not disclosed.